Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma

Technology appraisal guidance
Reference number: TA540
Published: 03 September 2018
Last updated: 01 May 2024

Evidence

Supporting evidence

Evaluation report
Final appraisal determination committee papers (PDF 2.05 MB)

Published:

03 September 2018
Appraisal consultation committee papers (PDF 24.12 MB)

Published:

03 September 2018